NCT06261359 - A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

October 31, 2026

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG

CEND-1

CEND-1 will be provided as concentrate for solution to be administered via IV injection.

DRUG

Gemcitabine

Gemcitabine will be provided as solution to be administered via IV infusion.

DRUG

Nab paclitaxel

Nab-paclitaxel will be provided as solution to be administered via IV infusion.

Trial Locations (1)

RECRUITING

Chinese People's Liberation Army (PLA) General Hospital, Beijing

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY